Why are patient advocacy groups silent on high drug prices?

It’s one of the enduring mysteries in the constant struggle to make medicine affordable: Patient advocacy groups remain largely on the sidelines, refusing to criticize the pharmaceutical industry for outrageously high prices. In Why are patient advocacy groups silent on high drug prices, which appeared earlier this year in Washington Monthly, I explain this seemingly inexplicable behavior.